Trial Profile
Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2020
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TEMPO LUNG 01; Tempo-Lung
- Sponsors Pierre Fabre
- 10 Oct 2019 Status changed from recruiting to completed.
- 18 Apr 2019 This trial has been completed in Poland, according to European Clinical Trials Database.
- 19 Jul 2017 The trial has been completed in Austria according to European Clinical Trials Database.